1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
SQZ Biotechnologies Company

SQZ Biotechnologies Company

SQZB
SQZ Biotechnologies CompanyUS flagOther OTC
0.02
USD
- -
- -
707,787.00Market Cap
SQZ Biotechnologies Company
SQZB
(Other OTC)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
TTM
FRC
0.8
1.08
3.89
0.98
0.73
0.41
Revenue per Share
-1.34
-1.8
-9.35
-2.49
-2.76
-2.43
Basic EPS, GAAP
1.37
-1.99
-8.21
-3
-2.92
-2.53
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
-3.06
-4.26
-23.46
-7.09
-9.54
-11.29
Book Value per Share
-3.02
-4.1
23.55
4.5
1.98
0.06
Tangible Book Value per Share
14
18
5
28
29
29
Basic Weighted Avg Shares
12
19
21
27
21
12
Sales/Revenue/Turnover
-176.83
-177.37
-243.16
-253.78
-360.57
-497.3
Operating Margin (%)
1
4
11
11
12
11
Depreciation Expense
-19
-32
-51
-69
-79
-72
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-166.83
-166.69
-240.6
-253.68
-377.88
-587.43
Profit Margin (%)
87
64
132
117
46
3
Working Capital
- -
33
39
60
21
19
LT Debt
-44
-74
127
124
57
2
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
ST Debt
4
3
2
LT Borrowings
- -
- -
- -
LT Finance Leases
20
20
19
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
29
29
29
Market Capitalization
16
8
2

Working Capital

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
44
28
12
Cash, Cash Equivalents & STI
40
25
10
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
13
10
9
Payables & Accruals
7
7
6
ST Debt
4
3
2
Deferred Revenue
1
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-53.9%
Free Cash Flow
- -
- -
1.6%
Net Income, GAAP
- -
- -
15.6%
Sales/Revenue/Turnover
- -
- -
-22.4%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
5
5
5
12
27
2022
3
3
3
12
21
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.59
-0.68
-0.8
- -
-2.49
2022
-0.75
-0.78
-0.77
- -
-2.76
2023
-0.6
-0.57
-0.8
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
4D Molecular Therapeutics, Inc. (FDMT)
Generex Biotechnology Corporation (GNBTQ)
Dimerix Limited (DXB.AX)
Agentix Corp. (AGTX)
Exelixis, Inc. (0IJO.L)
Cyclacel Pharmaceuticals, Inc. (CYCCP)
Business
SQZ Biotechnologies Company SQZ Biotechnologies Company (SQZB) operates as a clinical-stage biotechnology entity focused on cell therapies for cancer, autoimmune disorders, infectious diseases, and other serious conditions, utilizing proprietary Cell Squeeze technology for intracellular delivery via membrane disruption into various cell types including red blood cells, peripheral blood mononuclear cells, hematopoietic stem cells, T cells, NK cells, monocytes, and B cells; its platforms encompass SQZ Enhanced APC (eAPC) for tumor-specific CD8+ T cell activation, SQZ Activating Antigen Carriers (AAC) such as SQZ-AAC-HPV and SQZ-PBMC-HPV in Phase I trials for HPV16+ solid tumors like cervical, head-and-neck, anal, penile, vulvar, and vaginal cancers often combined with immuno-oncology agents, and SQZ Tolerizing Antigen Carriers (TAC) for inducing immune tolerance in autoimmune applications such as celiac disease. Founded in 2013 and headquartered in Watertown, Massachusetts, the company targets oncology, immunology, and infectious disease markets primarily in the United States with global research applicability. In a major strategic shift, SQZ sold substantially all assets—including over 400 patents, trademarks, intellectual property, proprietary equipment, and its MIT head license—to STEMCELL Technologies Canada Acquisitions Inc. for $11.8 million in early 2024, followed by shareholder approval of a plan of liquidation and dissolution filed on March 4, 2024, after which it maintains a minimal corporate presence via a PO Box in Wayland, Massachusetts, while directing Cell Squeeze-related inquiries to STEMCELL's licensing team.

Company News

APIChat

  • businesswire.com

    STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company

  • businesswire.com

    Asset Sale and Plan of Liquidation and Dissolution Approved by SQZB Shareholders

  • businesswire.com

    SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates

  • businesswire.com

    SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting

  • businesswire.com

    SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates